Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of patients to fulvestrant.

Bibliographic Details
Main Authors: Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner
Format: Article
Language:English
Published: Nature Publishing Group 2016-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms11579

Internet

https://doi.org/10.1038/ncomms11579

Similar Items